Russell Szmulewitz on Alternative Dosing of Abiraterone in Prostate Cancer Pharmacoeconomic Proof of Concept

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Elacestrant May Improve Outcomes for Postmenopausal Patients With Progressive ER-Positive HER2-Negative Metastatic Breast Cancer (1)

PALLAS Trial Addition of Adjuvant Palbociclib to Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer

Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer

Telemedicine Use Among U.S. Patients With Newly Diagnosed Cancer Impact of Socioeconomic Status

COVID-19 Infection After SARS–CoV-2 Messenger RNA Vaccination in Patients With Cancer